Lipid nanoparticles (LNPs) are one of the promising technologies for the in vivo delivery of short interfering RNA (siRNA). Modifying LNPs with polyethyleneglycol (PEG) is widely used to inhibit non-specific interactions with serum components in the blood stream, and is a useful strategy for maximizing the efficiency of active targeting.
Introduction
Since the discovery of short interfering RNA (siRNA) [1] , which induces specific gene silencing through RNA interference (RNAi) [2] , the focus of many researchers has been on realizing RNAi-based medicine for treating refractory diseases. Because of the characteristics of siRNA, which include hydrophilicity, a negative charge and high molecular weight, adequate delivery technology is essential for improving the bioavailability of siRNA.
Active targeting is a useful strategy for achieving the cell-specific delivery of payloads. Basically, active targeting involves the use of an appropriate ligand that recognizes the target cells. However, specific delivery sometimes cannot be achieved because of non-specific interactions of the vehicle used with biomolecules and elimination from the blood circulation by the reticuloendothelial system (RES), resulting in a decreased efficiency for ligand-mediated specific delivery to target cells.
Therefore, minimization of non-specific recognition by RES is important to maximize the efficiency of an active targeting agent.
Polyethyleneglycol (PEG) modification (PEGylation) is an accepted strategy for
inhibiting non-specific recognition by RES [3, 4] . PEGylation of the surface of nanoparticle results in formation of a fixed aqueous layer, which inhibits the adsorption of serum proteins through electrostatic and hydrophobic interactions [5] . However, after internalization into target cells, the aqueous layer also strongly inhibits interactions of the nanoparticles with the endosomal membrane, which reduces the efficiency of cytosolic delivery of the cargo. This issue is sometimes referred to as the PEG-dilemma [6] [7] [8] .
Many kinds of strategies have been developed to overcome the PEG-dilemma. One such strategy is the environment-responsive removal of the PEG from nanoparticles inside and/or outside of the target cells [7] . Among the various environments, the difference in pH between the blood circulation and endosomes/lysosomes is one of the most extensively investigated factors. PEGylation through a pH-labile linkage, such as an acetal, orthoester and hydrazone, is a useful strategy for adding a pH-sensitive functionality [9] [10] [11] [12] [13] [14] . However, While, in most studies, the pH-sensitive functionalities of these pH-labile linkages were examined in vitro, information concerning the pH-labile linkages in vivo is much less extensive. In addition, among these pH-labile linkages, a maleic anhydride derivative has some advantages including that the modification can be done in water and that fact that a pH-sensitivity of the final product can be controlled by slight modification of the chemical structure. Maleic anhydride derivatives have been applied only in a few polymer-based siRNA delivery systems but not in siRNA-loaded lipid nanoparticles (LNPs) [15] [16] [17] .
LNPs are one of the promising systems for delivering siRNA [18] [19] [20] [21] [22] . As the result of the recent development of novel cationic lipids by rational design and combinatorial screening approaches, the efficiency of siRNA delivery has been dramatically improved, especially in liver tissues [23] [24] [25] [26] [27] .
In the present study, we report on the development of siRNA-loaded LNPs for targeting hepatocytes using a hepatotropic ligand, N-acetyl-D-galactosamine (GalNAc) [28, 29] and modifying the LNPs with maleic anhydride. The use of maleic anhydride for PEG-modification resulted in a significant improvement in the hepatocyte targeting efficiency of the GalNAc-modified LNPs and in an improvement in factor 7 (F7) gene silencing activity. F7 gene silencing activity was further improved by optimizing the structure of the maleic anhydride (14-fold higher activity compared to that of the GalNAc-LNPs without PEGylation through maleic anhydride). These findings suggest that the strategy that involves a combination of a specific ligand and pH-labile PEG shielding would be useful for improving the active targeting efficiency of LNPs for siRNA delivery in vivo. 
Materials and methods

Animals
Female ICR mice, 4 weeks of age, were purchased from Japan SLC (Shizuoka, Japan).
The experimental protocols were reviewed and approved by the Hokkaido University Animal Care Committee in accordance with the guidelines for the care and use of laboratory animals.
Preparation of LNPs
A 90% t-BuOH solution containing YSK05/chol/chol-PEG 400 -amine/DMG-m PEG 2k at a molar ratio of 70/30/15/1.5 were prepared at a concentration of 7.5 mM total lipid. In case of GalNAc modification, 0.25 to 0.5 mol% of trivalent GalNAc ligand was added to the above solution. These lipid solutions were mixed with 0.4 mg/mL siRNA solution to be N/P ratio of 8. LNPs were prepared by gradually adding this mixture to 20 mM Citrate buffer (pH4.0) under vigorous mixing. The resulting LNP solution were diluted with 0.1 M HEPES buffer (pH9.5) and ultrafiltrated using Vivaspin Turbo-15 (MWCO 100 kDa, Sartorius) twice for removal of t-BuOH, adjustment of pH. The size and ζ-potential of the LNPs were measured by a Zetasizer Nano ZS ZEN3600 instrument (Malvern Instruments, Worcestershire, UK). The encapsulation efficiency and total concentration of siRNA were measured by a Ribogreen assay, as described previously [30] .
Modification of LNPs with maleic anhydride derivatives
To modify the LNPs with maleic anhydride derivatives, LNPs at a concentration of 10 mM total lipid suspended in 0.1 M HEPES buffer (pH9.5) was added to a dried powder of various (0 to 2.5) equivalents of CDM-m PEG 2k or CEM-m PEG 2k . The modified LNPs were preserved at 4˚C until used in experiments.
Measurement of the efficiency of maleic anhydride modification
The efficiency of surface modification was measured by detecting remaining primary amino groups using TNBS. The modified LNP solution was diluted with 0.1 M borate buffer (pH9.5) dissolving 0.4 mM TNBS and incubated for 30 min at 25˚C with gentle shaking (700 rpm). After the incubation, TritonX-100 was added to a final TritonX-100 concentration of 1.0 w/v%, and the absorbance at 420 nm was then measured and normalized by unmodified LNPs.
Measurement of hydrolysis rate
The rate of hydrolysis maleic acid amide was measured by detecting primary amino group using TNBS. 
Measurement of intrahepatic distribution of LNPs
ICR mice were intravenously injected with DiI (0.5 mol% of total lipid) labeled LNPs, which were diluted with PBS to become an appropriate concentration immediately prior to injection at a dose of 0.5 mg siRNA/kg. One hour after the injection, liver tissues were collected and stained with 20 µg/mL FITC-conjugated Isolectin B4. Intrahepatic distribution of the LNPs was observed using a Nikon A1
(Nikon Co. Ltd. Tokyo, Japan). Images were captured by ×60 objective.
2.10 Measurement of plasma coagulation factor 7 (F7) activity ICR mice were intravenously injected with the LNPs, which were diluted with PBS(-)
to become an appropriate concentration just before injection. Twenty-four hours after injection, mice were euthanized and blood was collected by cardiac puncture and processed to plasma using heparin. Plasma F7 activity were measured using a Biophen F7 chromogenic assay kit (Aniara Corporation, West Chester, OH, USA) according to manufacturer's protocol.
Statistical analysis
Results are expressed as the mean±SD. Statistical comparisons between two groups were evaluated by the Student's t-test and corrected by ANOVA for multiple comparisons.
Results
Preparation of LNPs
The LNPs used in this study were prepared by the t-BuOH dilution method as described previously [30] . The LNPs were composed of pH-sensitive cationic lipid, YSK05 (previously developed in our laboratory [30] ), cholesterol and m PEG 2k -DMG at a molar ratio of 70/30/1.5. In addition, 15 mol% of chol-PEG 400 -amine was inserted to the LNPs as a donor of primary amino groups which react with maleic anhydride [31] .
Modification with the chol-PEG 400 -amine resulted in an increase in the ζ-potential of the LNPs due to its cationic charge derived from primary amino groups and an approximately a 3-fold improvement in in vitro gene silencing activity ( Figure S1A , B).
The fusogenic activity of the LNPs was evaluated by the cancellation of FRET. As a model of an endosome, an anionic liposome labeled with a FRET pair (NBD-DOPE/Rho-DOPE) was mixed with the LNPs at pH6.0, which mimics the pH in acidic endosomes. Modification with the chol-PEG 400 -amine resulted in a significant improvement in the fusogenic activity of the LNPs with anionic liposomes ( Figure S1C ).
After the formation of the LNPs, the LNPs were reacted with CDM-m PEG 2k . The chemical structure of all components used for the LNPs is shown in Figure 1 . To confirm the pH-sensitive detachment of CDM-m PEG 2k , the recovery of primary amino groups was evaluated by a TNBS assay after the CDM-m PEG 2k -modified LNPs were incubated at pH 7.4 and 6.0. The recovery rate of the primary amino group was moderate at pH 7.4 and the half-life (t 1/2 ) was 45 min ( Figure 4A ). At 6.0, the t 1/2 was 6 min, which is 7.5-fold faster compared to pH 7.4 ( Figure 4A ). The detachment of CDM-m PEG 2k from the surface of the LNPs would result in the recovery of fusogenic activity of the LNPs with endosomal membranes due to reduced steric hindrance by the PEG layer (fixed aqueous layer) located on the surface of the LNPs. LNPs that were not modified with CDM-m PEG 2k rapidly fused with the anionic liposome which is used as a model endosome [32] , reaching a FRET cancellation of approximately 60% ( Figure 4B ).
On the other hand, the LNPs modified with CDM-m PEG 2k showed a lower fusogenic activity (FRET cancellation of approximately 20%) until 2 min after mixing, which results from the stealth function conferred by the PEG layer ( Figure 4B ). However, a rapid recovery of the fusogenic activity was found after a 2 min incubation period ( Figure 4B, arrow) . We also confirmed that the fusogenic activity of the CDM-m PEG 2k -modified LNPs was nearly fully recovered by pre-incubation for 1 hour at pH 6.0 before mixing with anionic liposomes ( Figure 4B ). These results suggest that the CDM-m PEG 2k modification did not inhibit the membrane fusion-mediated endosomal escape of the LNPs after cellular uptake due to the rapid detachment of the PEG layer in the acidic environment. 
In vivo active targeting
To target hepatocytes, LNPs were modified with0.5 mol% of a trivalent GalNAc ligand ( Figure 5A ). To evaluate the hepatocyte-targeting ability of the LNPs, mice were intravenously injected with 4 types of of LNPs (GalNAc (±), CDM-m PEG 2k (±)). At 60 minutes after injection, the intrahepatic distribution of the LNPs was observed using confocal fluorescent microscopy. Bare LNPs (GalNAc (-), CDM-m PEG 2k (-)) were detected on blood vessels of the liver ( Figure 5B , upper left) and other organs, including the lungs, heart and kidneys ( Figure S2 ), due to their cationic property ( Figure S1A ).
Modification with CDM-m PEG 2k clearly inhibited non-specific adsorption to blood vessels in various organs ( Figure S2 ). However, the LNPs that were modified with CDM-m PEG 2k failed to accumulate in hepatocytes due to the absence of the GalNAc ligand ( Figure 5B , upper right). Moreover, GalNAc-modified LNPs also failed to accumulate in hepatocytes ( Figure 5B , lower left). On the other hand, significant levels of LNPs that were modified with both GalNAc and CDM-m PEG 2k accumulated in hepatocytes ( Figure 5B , lower right). To confirm that the improvement in intrahepatic distribution results in an increase in gene silencing activity in hepatocytes, siRNA targeting coagulation factor 7 (siF7), a hepatocyte-specific gene, was formulated in the 4 types of LNPs (GalNAc (±), CDM-m PEG 2k (±)) and intravenously injected at a dose of 0.5 mg siRNA/kg. Bare LNPs showed approximately a 40% gene silencing under these experimental conditions ( Figure 5C ). The LNPs with a single modification of GalNAc or CDM-m PEG 2k showed a slightly improved activity but the improvement was not statistically significant ( Figure 5C ). On the other hand, modification with both
GalNAc and CDM-m PEG 2k resulted in a significant improvement in activity (approximately 90% gene silencing) ( Figure 5C ), which is reflected by a change in intrahepatic distribution ( Figure 5B ). To confirm that the uptake of the LNPs that were modified with both GalNAc and CDM-m PEG 2k is mediated by the GalNAc/ASGPR pathway, mice were co-injected with galactose, a competitive inhibitor of the interaction between GalNAc and ASGPR. As expected, F7 silencing activity was significantly reduced when galactose was co-injected ( Figure S3 ), suggesting that the uptake of the LNPs by hepatocytes proceeds in a GalNAc-mediated active targeting manner. A significant reduction in F7 activity was observed only after the injection of siF7, but not siRNA targeting the human polo-like kinase 1 (siPLK1), suggesting that the silencing of F7 expression is siRNA sequence-specific ( Figure S4A ). Moreover, no significant modulation in the expression of several cell-specific marker genes (CD11b, CD31 and CD45) was found, indicating that the developed LNPs are able to induce the specific silencing of the target gene with negligible off-target effects ( Figure S4B ). No elevation in plasma alanine transaminase (ALT) and aspartate transaminase (AST) levels and no loss of body weight change was observed at 24 hrs after the injection of the LNPs modified with both GalNAc and CDM-m PEG 2k at a dose of 0.5 mg siRNA/kg, which was a highest dose used in this study ( Figure S5 ). To modify the LNPs with CDM-m PEG 2k , chol-PEG 400 -amine was inserted as a donor of primary amino groups, which react with maleic anhydride [31] . A spacer, PEG 400 , between the cholesterol (anchor) and primary amino group played an important role in realizing the pH-sensitive detachment of CDM-m PEG 2k from the surface of the LNPs.
Indeed, in the case where phosphatidylethanolamine (PE), instead of chol-PEG 400 -amine, was used as a donor of primary amino group, the hydrolysis rate of the maleic acid amide bond was much slower and the particles were unresponsive to a change in pH (unpublished data). Hydrolysis of the maleic acid amide was achieved via the nucleophilic attack of the maleic acid carboxylate anion opposite the carbonyl carbon of the maleic acid amide bond. The protonated tertiary amino group (cation) of YSK05 can electrostatically bind to negative carboxylate anions, resulting in the inhibition of the nucleophilic attack for hydrolysis of maleic acid amide bond. Because the primary amino group of PE must be very close to the tertiary amino group of the YSK05, an inhibitory effect would be easy to occur. Under this situation, a spacer, PEG 400 , was introduced between the hydrophobic anchor and the primary amino group in order to separate carboxylate anion from YSK05 and to minimize the risk of an inhibitory effect.
Indeed, a rapid and pH-dependent hydrolysis was observed in our system ( Figure 4A ). However, to clarify the relationship between spacer length and the inhibitory effect, a detailed examination of the spacer length will be needed. Concerning in vivo, in a previous study, we found that the t 1/2 for GalNAc-mediated blood clearance is approximately 25 min, and 1.5 hour is sufficient for the GalNAc-modified LNPs to accumulate in hepatocytes (unpublished data). Therefore, the accumulation of the LNP in hepatocytes was clearly enhanced by modification with both GalNAc and CDM-m PEG 2k ( Figure 5B), but it was further enhanced by replacing the CDM with CEM, which shows a lower hydrolysis rate ( Figure 6C and S6) .
Reflected by enhanced accumulation in hepatocytes, gene silencing activity for the same cells was clearly improved (Figure 5C and 6D ). This fact suggests that PEGylation of the LNPs through the pH-labile maleic anhydride had no effect on the magnitude of endosomal escape through membrane fusion.
PEGylation of the LNPs through maleic acid amide results, not only in the formation of a thick fixed aqueous layer on the surface of the LNPs, but also in reversing the charge of the LNPs from positive to negative (Figure 2A) . Because a positive charge causes non-specific interactions with negatively charged serum proteins and cell surfaces ( Figure S2 ), the characteristics of maleic anhydride, the reversal of charge, is useful in terms of suppressing the cationic charge of the LNPs in the blood stream and to expand the opportunity for the cationic LNPs to be used for in vivo applications.
To our knowledge, this is first report to demonstrate that PEG-modification through maleic anhydride improves the targeting capability and efficiency of the drug delivery of ligand-modified LNPs in vivo. Importantly, the fact that the ED 50 of the optimized LNPs in F7 model mice is a level relevant to clinical applications, suggests that the current strategy has considerable potential for clinical use.
Conclusion
In the present study, we reported on the development of siRNA-loaded LNPs that are modified with both a specific ligand and PEG via maleic acid amide bonding. The rapid and pH-sensitive detachment of PEG moiety and re-activation of fusogenisity was confirmed. In vivo, an enhanced efficiency of hepatocyte-targeting and gene silencing activity were confirmed. These lines of the evidence suggest that this strategy, i.e., modifying an LNP with a combination of a specific ligand and maleic anhydride-PEG, can be useful for achieving the efficient LNP-mediated delivery of siRNAs to specific sites. 
